Study of CP-675,206 in Refractory Melanoma
Completed · Phase 2
Conditions studied: Refractory Melanoma
In brief
CP-675,206 is a fully human monoclonal antibody (mAb). It binds to the CTLA4 molecule, which is expressed on the surface of activated T lymphocytes. CP-675,206 is thought to stimulate patients' immune systems to attack their tumors. CP-675,206 is not expected to have a direct effect on tumor cells. CP-675,206 been shown to induce durable tumor responses in patients with metastatic melanoma in Phase 1 and Phase 2 clinical studies.
Key facts
- Study ID
- NCT00254579
- Run by
- AstraZeneca
- People needed
- 251
- Starts
- 2005-12-01
- Expected to finish
- 2009-12-01
- Last updated by the study team
- 2012-06-07
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Surgically incurable Stage III or IV melanoma
- One prior systemic treatment for metastatic melanoma
- Measurable disease
- Eastern Cooperative Oncology Group (ECOG) PS = 0 or 1
You may not qualify if…
- Melanoma of ocular origin
- Received prior vaccine
- Received prior CTLA4-inhibiting agent
- History of, or significant risk for, chronic inflammatory or autoimmune disease
- Potential requirement for systemic corticosteroids
Where it is running
- Research Site — Bentonville, Arkansas, United States
- Research Site — Fayetteville, Arkansas, United States
- Research Site — Little Rock, Arkansas, United States
- Research Site — Los Angeles, California, United States
- Research Site — Los Angeles, California, United States
- Research Site — Aurora, Colorado, United States
- Research Site — Stamford, Connecticut, United States
- Research Site — Ocoee, Florida, United States
- Research Site — Orlando, Florida, United States
- Research Site — Orlando, Florida, United States
- Research Site — Chicago, Illinois, United States
- Research Site — Indianapolis, Indiana, United States
- Research Site — Indianapolis, Indiana, United States
- Research Site — Indianapolis, Indiana, United States
- Research Site — Louisville, Kentucky, United States
- Research Site — Baltimore, Maryland, United States
- Research Site — Boston, Massachusetts, United States
- Research Site — Ann Arbor, Michigan, United States
- Research Site — Buffalo, New York, United States
- Research Site — New York, New York, United States
- Research Site — Chapel Hill, North Carolina, United States
- Research Site — Durham, North Carolina, United States
- Pfizer Investigational Site — Columbus, Ohio, United States
- Research Site — Columbus, Ohio, United States
- Research Site — Scottsdale, Arizona, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.